[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Malard Y, De Lara CT, MacGrogan G, Bussières E, Avril A, Picot V, Bui B, Coindre JM: [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period]. J Gynecol Obstet Biol Reprod (Paris); 2004 Nov;33(7):589-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period].
  • [Transliterated title] Sarcomes primitifs du sein: à propos d'une série rétrospective de 42 cas traités à l'Institut Bergonié sur une période de 32 ans.
  • To analyze Primary breast sarcomas (PBS).
  • RESULTS: The median age at diagnosis was 56.9 years (24-81 years).
  • Patients with angiosarcoma and those with malignant cystosarcoma constituted distinct populations.
  • The 10-year OS and DFS rates were 53% and 55% for angiosarcoma patients and 89% and 100% for cystosarcoma patients (p=0.009 and 0.01 respectively).
  • [MeSH-major] Breast Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / mortality. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Humans. Mastectomy. Middle Aged. Phyllodes Tumor / drug therapy. Phyllodes Tumor / mortality. Phyllodes Tumor / radiotherapy. Phyllodes Tumor / surgery. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15550877.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Ueyama Y, Abe Y, Ohnishi Y, Sawa N, Hatanaka H, Handa A, Tokuda Y, Yamazaki H, Kijima H, Tamaoki N, Nakamura M: In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts. Oncol Rep; 2000 Mar-Apr;7(2):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts.
  • Malignant cystosarcoma phyllodes (MCSP) is a rare breast tumor.
  • We studied the chemosensitivity of these two MCSP tumor xenografts to anticancer drugs in vivo.
  • We also examined the expression of multidrug resistance-related proteins such as p-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) by immunohistochemical analysis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Cyclophosphamide / pharmacology. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Phyllodes Tumor / drug therapy. Vincristine / pharmacology
  • [MeSH-minor] Animals. Drug Resistance, Neoplasm. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. P-Glycoprotein / biosynthesis. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671667.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


3. Yonemoto T, Tatezaki S, Ishii T, Hagiwara Y, Inoue M: Multiple primary cancers in patients with osteosarcoma: influence of anticancer drugs and genetic factors. Am J Clin Oncol; 2004 Jun;27(3):220-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary cancers in patients with osteosarcoma: influence of anticancer drugs and genetic factors.
  • The diagnoses of second cancer in group A consisted of two acute myelogenous leukemias, two breast carcinomas, one malignant phyllodes tumor of breast, and one ovarian carcinoma.
  • The diagnoses of first cancer in group B consisted of one adrenocortical carcinoma, one malignant teratoma of sacrum, and one ovarian carcinoma (yolk sac tumor).
  • Anticancer drugs and genetic factors are presumed to be concerned with occurrence of second cancer.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15170137.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the breast.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • Majority of the series include both stromal and cystosarcoma phyllodes, only a few hundred cases of sarcomas other then cystosarcoma are reported.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 19 patients with primary sarcoma of the breast treated between 1982 and 2002.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Failure was local in five, opposite breast in one, and both local and distant in two.
  • CONCLUSIONS: Primary sarcomas of the breast are aggressive tumors.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Jaukovic LDj, Ajdinovic BZ, Jankovic ZD, Strbac M: Technetium-99m-tetrofosmin in diagnosis of breast cancer and axillary lymph node involvement. Nucl Med Rev Cent East Eur; 2006;9(1):30-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m-tetrofosmin in diagnosis of breast cancer and axillary lymph node involvement.
  • BACKGROUND: The aim of this study was to evaluate the accuracy of breast cancer seeking agent Tc-99m-Tetrofosmin in the detection of breast malignancy and axillary lymph node metastases.
  • MATERIAL AND METHODS: Twenty-eight female patients (mean age 52.4) with 30 breast lesions suspected of malignancy were enrolled in the study.
  • All the patients underwent clinical investigation, Tc-99m Tetrofosmin scintimammography (SMM), mammography (MM) and biopsy/surgery for final histopathologic diagnosis.
  • RESULTS: SMM scans of 30 breast lesions were compared to the definitive histopathology findings (HP) using decision matrix.
  • In the group of 23 patients with positive SMM scans 19 had breast malignancy: 15 infiltrating ductal cancer, three patients with one infiltrating lobular, one papillary, one colloidal cancer and one patient with cystosarcoma phyllodes-malignant type.
  • SMM detected primary breast malignancy with 95% sensitivity, 60% specificity and 83% accuracy.
  • CONCLUSION: Our results showed that SMM might be useful as a complementary test to improve the sensitivity and specificity of conventional imaging modalities, although SMM in the staging of breast carcinoma was less reliable.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / radionuclide imaging. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791801.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down






Advertisement